RenovoRx Aktie

RenovoRx für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3CYE8 / ISIN: US75989R1077

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.08.2025 00:48:37

RenovoRx Revenue Jumps 28 Percent in Q2

RenovoRx (NASDAQ:RNXT), a medical technology company focused on targeted cancer therapy delivery, reported earnings on August 14, 2025. As sales of its RenovoCath device grew to $422,000 (GAAP), surpassing the analyst consensus of $329,633 (GAAP) by 28.0%. Earnings per share (EPS) (GAAP) also landed better than expected, at a net loss of ($0.08) compared to the estimated loss of ($0.085). While the company posted a larger net loss (GAAP) than the prior year, overall results show commercial momentum in both sales and new cancer center approvals. Despite ongoing losses, the quarter highlighted emerging commercial traction and progress in its pivotal Phase III TIGeR-PaC trial. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. RenovoRx is advancing precision oncology through targeted delivery of chemotherapy and other therapies directly to solid tumors. Its flagship product, the RenovoCath medical device, enables the targeted delivery of chemotherapy via blood vessels at the tumor site. The company's core focus is improving outcomes for difficult-to-treat cancers with reduced side effects, primarily through its Trans-Arterial Micro-Perfusion (TAMP) therapy platform.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu RenovoRx Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Q2 Holdings Inc 56,50 0,00% Q2 Holdings Inc
RenovoRx Inc Registered Shs 1,27 -5,22% RenovoRx Inc Registered Shs